Goldman Sachs Group Inc Kymera Therapeutics, Inc. Transaction History

Goldman Sachs Group Inc

  • $605 Billion
  • Q3 2024

A detailed history of Goldman Sachs Group Inc transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 224,831 shares of KYMR stock, worth $8.86 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
224,831
Previous 462,309 51.37%
Holding current value
$8.86 Million
Previous $13.8 Million 22.89%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
SELL
$30.16 - $52.4 $7.16 Million - $12.4 Million
-237,478 Reduced 51.37%
224,831 $10.6 Million
Q2 2024

Aug 13, 2024
BUY
$29.85 - $39.42 $351,961 - $464,801
11,791 Added 2.62%
462,309 $13.8 Million
Q1 2024

May 15, 2024
SELL
$22.9 - $43.57 $5.13 Million - $9.77 Million
-224,137 Reduced 33.22%
450,518 $18.1 Million
Q4 2023

Feb 13, 2024
BUY
$10.97 - $26.84 $5.16 Million - $12.6 Million
469,947 Added 229.57%
674,655 $17.2 Million
Q3 2023

May 14, 2024
SELL
$13.9 - $23.88 $6.53 Million - $11.2 Million
-469,947 Reduced 69.66%
204,708 $2.85 Million
Q3 2023

Nov 14, 2023
SELL
$13.9 - $23.88 $1.9 Million - $3.27 Million
-136,837 Reduced 40.06%
204,708 $2.85 Million
Q2 2023

May 14, 2024
BUY
$22.4 - $34.92 $1 Million - $1.56 Million
44,702 Added 15.06%
341,545 $7.85 Million
Q2 2023

Aug 14, 2023
BUY
$22.4 - $34.92 $1 Million - $1.56 Million
44,702 Added 15.06%
341,545 $7.85 Million
Q1 2023

May 14, 2024
SELL
$24.84 - $38.75 $1.02 Million - $1.59 Million
-41,087 Reduced 12.16%
296,843 $8.8 Million
Q1 2023

May 11, 2023
SELL
$24.84 - $38.75 $1.02 Million - $1.59 Million
-41,087 Reduced 12.16%
296,843 $8.8 Million
Q4 2022

May 14, 2024
BUY
$19.57 - $30.92 $22,916 - $36,207
1,171 Added 0.35%
337,930 $8.43 Million
Q4 2022

Feb 13, 2023
BUY
$19.57 - $30.92 $22,916 - $36,207
1,171 Added 0.35%
337,930 $8.43 Million
Q3 2022

May 14, 2024
BUY
$20.91 - $34.27 $1.24 Million - $2.04 Million
59,495 Added 21.46%
336,759 $7.33 Million
Q3 2022

Nov 10, 2022
BUY
$20.91 - $34.27 $1.24 Million - $2.04 Million
59,495 Added 21.46%
336,759 $7.33 Million
Q2 2022

May 14, 2024
SELL
$14.13 - $42.55 $5.62 Million - $16.9 Million
-397,391 Reduced 58.9%
277,264 $5.46 Million
Q2 2022

Aug 15, 2022
BUY
$14.13 - $42.55 $471,065 - $1.42 Million
33,338 Added 13.67%
277,264 $5.46 Million
Q1 2022

May 16, 2022
SELL
$35.3 - $64.68 $842,399 - $1.54 Million
-23,864 Reduced 8.91%
243,926 $10.3 Million
Q4 2021

Feb 14, 2022
BUY
$49.91 - $65.56 $4.37 Million - $5.74 Million
87,583 Added 48.6%
267,790 $17 Million
Q3 2021

Nov 10, 2021
BUY
$47.8 - $66.66 $8.61 Million - $12 Million
180,207 New
180,207 $10.6 Million

Others Institutions Holding KYMR

# of Institutions
182
Shares Held
64.3M
Call Options Held
50.6K
Put Options Held
81.7K
View Full List

About Kymera Therapeutics, Inc.

KYMR Quotes by TradingView
  • Ticker KYMR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 54,705,800
  • Market Cap $2.16B
  • Description
  • Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...
More about KYMR
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email